Physician Payments Sunshine Act

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The Physician Payments Sunshine Act is a 2010 United States healthcare law to increase transparency of financial relationships between health care providers and pharmaceutical manufacturers.

About[edit]

The Sunshine Act requires manufacturers of drugs, medical devices, biological and medical supplies covered by the three federal health care programs Medicare, Medicaid, and State Children's Health Insurance Program (SCHIP) to collect and track all financial relationships with physicians and teaching hospitals and to report these data to the Centers for Medicare and Medicaid Services (CMS). The goal of the law is to increase the transparency of financial relationships between health care providers and pharmaceutical manufacturers and to uncover potential conflicts of interest.[1] The bill allows states to enact "additional requirements", as six states already had industry-pay disclosure laws.[2]

In 2013, the American Medical Association offered physicians training to understand the Sunshine Act.[3]

History[edit]

The Sunshine Act was first introduced in 2007 by senior US Senator Charles Grassley, a Republican from Iowa and Senator Herb Kohl from Wisconsin, a member of the Democratic Party.[4] The act was introduced independently and failed. After debate by various groups [2] it was enacted along with the 2010 Patient Protection and Affordable Care Act.[citation needed]

In 2011, it was proposed to use identification systems on tracked physicians.[5]

On September 30, 2014, the Centers for Medicare and Medicaid Services reported payment information on its Open Payment Program website for the first time, the data from 2012.[6]

Criticism[edit]

In 2012 it was suggested that the act may have a limited effect on prescribing and on expenditures.[7]

A 2015 opinion piece in JAMA stated that the value of transparency was beyond dispute, but "the true value of the database remains uncertain and probably too early to ascertain".[8]

International comparison[edit]

There is no agreement on appropriate standards of disclosure internationally.[9]

Australia was one of the first countries that has, since mid-2007, required reporting of details of every industry-sponsored event. Data are publicly posted, updated every six months and downloadable as pdf only. A 2009 study found modest expenditure at individual events, but high cumulatively, particularly for prescribers of high cost drugs like oncologists, endocrinologists, and cardiologists. It concluded disclosure requirements fell short of what is required and proposed more comprehensive data collections.[9]

References[edit]

  1. ^ "S.301 - Physician Payments Sunshine Act of 2009 - 111th Congress (2009-2010)". Library of Congress (Congress.gov). 2009. Retrieved 2017-04-13. 
  2. ^ a b O'Reilly, Kevin B. (23 February 2009). "'Sunshine' bill sets $100 trigger for disclosing drug industry pay to doctors". American Medical News. Retrieved 3 June 2013. 
  3. ^ Lazarus, Jeremy (12 April 2013). "The Physician Payment Sunshine Act is here: Are you ready?". kevinmd.com. Retrieved 3 June 2013. 
  4. ^ Campbell, E. G. (2007). "Doctors and Drug Companies — Scrutinizing Influential Relationships". New England Journal of Medicine. 357 (18): 1796–1797. doi:10.1056/NEJMp078141. PMID 17978288. 
  5. ^ Carpenter, D. (2011). "A Unique Researcher Identifier for the Physician Payments Sunshine Act". JAMA: The Journal of the American Medical Association. 305 (19): 2007–2008. doi:10.1001/jama.2011.651. PMC 3143068Freely accessible. PMID 21586717. 
  6. ^ "Physician Financial Transparency Reports (Sunshine Act)". American Medical Association. 2013. Retrieved 3 June 2013. 
  7. ^ Pham-Kanter G, Alexander GC, Nair K (2012). "Effect of financial disclosure laws on physician prescribing". Archives of Internal Medicine. 172: 819–821. doi:10.1001/archinternmed.2012.1210. PMC 4007047Freely accessible. PMID 22636826. 
  8. ^ Perlis, Roy H.; Perlis, Clifford S. (2016-05-16). "Physician Payments from Industry Are Associated with Greater Medicare Part D Prescribing Costs". PLoS ONE. 11 (5). doi:10.1371/journal.pone.0155474. ISSN 1932-6203. PMC 4868346Freely accessible. PMID 27183221. 
  9. ^ a b Jane Robertson; Ray Moynihan; Emily Walkom; Lisa Bero; David Henry (3 November 2009). "Mandatory Disclosure of Pharmaceutical Industry-Funded Events for Health Professionals". PLOS Medicine. 6: e1000128. doi:10.1371/journal.pmed.1000128. Retrieved 8 January 2015. 

External links[edit]